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0022-2836 © 2010 Elsevier Ltd. Open accePlasmodium falciparum malaria remains one of the world's leading causes of
human suffering and poverty. Each year, the disease takes 1–3 million lives,
mainly in sub-Saharan Africa. The adhesion of infected erythrocytes (IEs) to
vascular endothelium or placenta is the key event in the pathogenesis of
severe P. falciparum infection. In pregnant women, the parasites express a
single and unique member of the P. falciparum erythrocyte membrane
protein 1 (PfEMP1) family named VAR2CSA, which is associated with the
ability of the IEs to adhere specifically to chondroitin sulphate A (CSA) in
the placenta. Several Duffy-binding-like domains from VAR2CSA mole-
cules have been shown in vitro to bind to CSA, but it has also been
demonstrated that Duffy-binding-like domains from PfEMP1 proteins other
than VAR2CSA can bind CSA. In addition, the specificity of the binding of
VAR2CSA domains to glycosaminoglycans does not match that of
VAR2CSA-expressing IEs. This has led to speculation that the domains of
native VAR2CSA need to come together to form a specific binding site or
that VAR2CSA might bind to CSA through a bridging molecule. Here, we
describe the expression and purification of the complete extracellular region
of VAR2CSA secreted at high yields from insect cells. Using surface
plasmon resonance, we demonstrate that VAR2CSA alone binds with
nanomolar affinity to human chondroitin sulphate proteoglycan and with
significantly weaker affinity to other glycosaminoglycans, showing a
specificity similar to that observed for IEs. Antibodies raised against full-
length VAR2CSA completely inhibit recombinant VAR2CSA binding, as
well as parasite binding to chondroitin sulphate proteoglycan. This is the
first study to describe the successful production and functionality of a full-
length PfEMP1. The specificity of the binding and anti-adhesion potency of
induced IgG, together with high-yield production, encourages the use of
full-length PfEMP1 in vaccine development strategies.© 2010 Elsevier Ltd.Open access under CC BY license. Edited by J. Karn Keywords: malaria; PfEMP1; VAR2CSA; vaccine; CSAedical Parasitology, Øster Farimagsgade 5, Building 22, PO Box 2099, 1014
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827Expression of Functional Full-Length VAR2CSAIntroduction‡Available at Sanger.ac.ukInfections are often initiated by the attachment of
a pathogen to a host receptor present on the
endothelium (reviewed by Yamada and Sugahara1).
Understanding the structure–function relationship
between pathogen ligand and host receptor is
important for the design of effective vaccines and
drugs targeting this interaction. Plasmodium falci-
parum malaria remains one of the leading causes of
human suffering and poverty in the world
(reviewed by Sachs and Malaney2). The adhesion
of infected erythrocytes (IEs) to vascular endotheli-
um or placental tissue is a key event in the
pathogenesis of severe P. falciparum infection. By
binding to receptors in the vascular bed, the
parasites avoid being filtered through the spleen,
where they are removed from the circulation.3
Adhesion of IEs to the vascular endothelium or the
placental tissue is mediated by members of the P.
falciparum erythrocyte membrane protein 1
(PfEMP1) family, which are encoded by the poly-
morphic multicopy var gene family.4–7 PfEMP1
proteins are large molecules (150–350 kDa) contain-
ing two to eight extracellular domains. During
infection, parasites expressing PfEMP1 proteins
mediate adhesion to a variety of human receptors.
Among the best studied receptors are CD36, which
is present in platelets and endothelial cells, and
intercellular adhesion molecule-1, which is present
in the endothelial lining (reviewed by Rowe et al.8).
In pregnant women, the parasites express a single
and unique variant of PfEMP1 named VAR2CSA,
which enables IEs to adhere to the chondroitin
sulphate A (CSA) chains of chondroitin sulphate
proteoglycans (CSPGs) in the placenta but weakly to
other glycosaminoglycans (GAGs).9–11
VAR2CSA is a large 350-kDa protein comprising
six Duffy-binding-like (DBL) domains and three
larger interdomain regions. Knockout studies of the
var2csa gene have demonstrated the essential role of
VAR2CSA in CSA binding, preventing the parasite
from regaining the ability to bind to CSA.12,13
Antibodies to the surface-expressed VAR2CSA
protein are acquired by women who are exposed
to malaria during pregnancy, and high levels of anti-
VAR2CSA antibodies at delivery are associated with
protection from low-birth-weight babies,10 one of
the major complications of pregnancy-associated
malaria (PAM). Antibodies targeting VAR2CSA
presumably abrogate or prevent binding to the
vascular bed and thus protect against the adverse
effects of the disease. VAR2CSA is recognized as the
leading PAM vaccine candidate, and antibodies to
single domains have, to varying degrees, been found
to inhibit parasite binding to CSA.14,15
Several DBL domains from VAR2CSA molecules
have been shown in vitro to bind to CSA.16–20
However, it has also been demonstrated that single
DBL domains from other PfEMP1 proteins can bind
CSA, although these proteins are not implicated
in placental malaria.20 In addition, single DBLdomains bound with roughly equal affinity to
different glycans, whereas VAR2CSA-mediated
binding of IEs is highly specific for CSA. Instead, it
has been shown that the measured interaction
between recombinant VAR2CSA domains and
CSA in vitro is primarily electrostatic and indepen-
dent of the structure of the GAG.20,21 This indicates
that either the CSA-binding region of VAR2CSA
comprises regions from multiple domains that come
together only in the intact protein, with the
possibility that some of the nonspecific binding
regions exposed in recombinant domains are buried
in native VAR2CSA, or the interaction between
native VAR2CSA on the IE surface and CSA is
mediated through another molecule.
Analysis of the structure–function relationship of
PfEMP1 proteins has been hampered by technical
difficulties in purifying native protein and the
inability to express the entire extracellular region
of PfEMP1 as recombinant constructs. Here, we
describe the cloning and production of the first full-
length extracellular part of a PfEMP1 protein,
VAR2CSA, in a secreted and soluble form. This
protein binds specifically and with high affinity to
human chondroitin sulphate proteoglycan (CSPG-h)
in a CSA-dependent manner and induces antibodies
that are able to potently react with native VAR2CSA
on IEs and inhibit the binding of IEs to CSPG.Results
Cloning, production, and purification of the
full-length extracellular part of VAR2CSA
A synthetic var2csa gene was designed based on
the new annotation of the var2csa gene from the
FCR3 parasite genome‡. Full-length VAR2CSA
(FV2) was cloned to allow translation from the N-
terminal methionine (M1) to amino acid F2649,
which is located before the putative transmembrane
region. FV2 was secreted into the supernatant as a
soluble protein (Fig. 1a), with only a small amount
of protein detectable in cell pellets. FV2 protein was
produced and secreted as a monomer (Fig. 1a and c).
Nonreduced protein migrates on SDS-PAGE as two
bands, which are reduced to a single band. The
majority of the protein is present in the fastest
migrating band, which is the size expected of a
nonreduced protein. To examine whether the two
folding variants observed in nonreduced SDS-PAGE
were due to different glycosylation patterns, we
produced the protein in the presence of tunicamy-
cin, which blocks glycosylation. However, nongly-
cosylated FV2 also migrated as two bands, although
of a smaller size (data not shown).
To compare the efficiency of three different
protein-capturing techniques [immobilized metal
ion affinity chromatography (IMAC), ion exchange
Fig. 1. Production and purifica-
tion of FV2. (a) SDS-PAGE of
recombinant VAR2CSA (FV2) pu-
rified on an IMAC column: re-
duced (R) and nonreduced (NR).
(b) SDS-PAGE of FV2 purified on a
1-ml HisSelect column (Ni2+), a 1-
ml Capto S HP column (IEX), and a
1-ml Heparin HP column (Hep).
Twenty microliters of a 1:240 dilu-
tion of each purification was load-
ed for comparison of yield. (c) Size-
exclusion chromatography on a
Superdex-200 column (GE Health-
care) of IMAC-purified FV2.
Fig. 2. Recombinant VAR2CSA binds specifically to
CSPG with subnanomolar affinity. (a) Human placental
CSPG was coupled to the surface of a Biacore chip, and
responses were measured after the injection of 10 nM,
15 nM, or 20 nM of the extracellular region of VAR2CSA
(FV2) through the chip surface. (b) Competition experi-
ments in which 10 nM FV2 was incubated with different
concentrations of (●) hyaluronic acid, (□) HSPG, (♦)
dermatan sulphate, (◊) CSA, (○) CSC, (▪) heparin, and (×)CSPG-b before the assessment of binding to a CSPG-h-
coated Biacore chip surface.
828 Expression of Functional Full-Length VAR2CSA(IEX), and affinity chromatography (AC)], we
loaded equal amounts of culture supernatant on a
1-ml HisSelect column (IMAC), a 1-ml HiTrap Capto
S column (IEX), and a 1-ml HiTrap Heparin HP
column (AC), and we eluted bound protein with
either imidazole (IMAC) or a NaCl chloride gradient
(IEX and AC), as described in Materials and
Methods. Figure 1b shows the purified protein,
and we found that IMAC yields around 1 mg of FV2
per liter of culture supernatant, whereas IEX and AC
yield around 2 mg/L and 4 mg/L, respectively. Gel
filtration of the IMAC-purified protein shows that
FV2 is monomeric also in the absence of SDS (Fig.
1c). The monomeric nature of FV2 was also
confirmed by analytical ultracentrifugation studies
(data not shown).
GAG-binding properties of recombinant
VAR2CSA
In previous studies, we used a surface-plasmon-
resonance-based assay to study the binding of
individual domains from VAR2CSA to CSPG-
h coupled to the surface of a Biacore chip.21 This
revealed that the DBL3X and DBL6ɛ domains of
VAR2CSA bind to CSPG-h with mid-micromolar
affinities (33 μM for DBL3X and 80 μM for DBL6ɛ).21
Here, we passed different concentrations of recom-
binant FV2 over a similar CSPG-coupled surface,
measuring the binding and dissociation of the
protein from the chip. The data fitted to a one-to-
one binding model with a Kd of 0.36 nM, an
association constant of 7.3×106 M− 1 s−1, and a
dissociation constant of 2.6×10−3 s−1 (Fig. 2a).
Therefore, the intact extracellular part of VAR2CSA
binds to CSPG-h with an affinity some 100,000-fold
greater than that observed for single recombinant
domains.
Fig. 3. Purified IgG raised against recombinant
VAR2CSA inhibits the binding of VAR2CSA to CSPG.
The extracellular region of VAR2CSA (FV2) at a concen-
tration of 10 nM was incubated with different concentra-
tions of purified IgG raised against (●) FV2, (♦) DBL4ɛ
domain of VAR2CSA, (▪) VAR1 DBL3γ, (□) prebleed,and (○) CIDR VAR4 before the assessment of binding to a
CSPG-h-coated Biacore chip surface.
829Expression of Functional Full-Length VAR2CSAWe next tested the GAG specificity of FV2.
Previous studies have shown that the single
DBL3X and DBL6ɛ domains from VAR2CSA lack
the binding specificity observed for VAR2CSA-
expressing IEs, with many GAGs able to compete
for binding with CSPG. Indeed, the greater is the
degree of sulphation, the more strongly a GAG
competes.21 We performed a similar experiment to
assess the binding specificity of VAR2CSA to CSPG-
h. Seven different GAGs were used in these
inhibition studies: hyaluronic acid from human
umbilical cord, bovine CSA and chondroitin sul-
phate C (CSC), dermatan sulphate, heparan sul-
phate proteoglycan (HSPG), heparin, and decorin
[bovine chondroitin sulphate proteoglycan (CSPG-
b)]. These GAGs are different in terms of sulphation,
negative charge, and glycan backbone structure. In
each case, FV2 at a concentration of 10 nM was
preincubated with different concentrations of GAGs
before being passed over a CSPG-h-coated Biacore
chip surface.
The various GAGs showed very different profiles
in blocking the binding of FV2 to CSPG-h (Fig. 2b).
Nonsulphated hyaluronic acid had no effect, and
HSPG had very little effect, whereas the chondroitin
sulphates (CSPG-b, CSA, CSC, and dermatan
sulphate) and the most sulphated GAG (heparin)
showed more significant inhibition. The strongest
effects were detected with the CSA-containing
GAGs bovine CSA and CSPG-b, with CSPG-b
causing almost complete inhibition at 1 ng/ml.
CSPG-b is a proteoglycan containing CSA chains
that resembles human placental CSPG in structure
and sulphation pattern.22 Therefore, the glycan that
is most similar to the native CSPG showed the
greatest affinity for recombinant FV2. This suggests
that the ability to selectively bind to low-sulphated
CSA chains observed for VAR2CSA-expressing IEs
is due to the selectivity of the extracellular region of
the VAR2CSA protein. While this does not rule out
other CSA-specific proteins on the IE surface, these
are not necessary to explain CSA-specific binding of
VAR2CSA.
Inhibition of the CSA binding of recombinant
VAR2CSA using VAR2CSA-specific IgG
Antibodies were induced against the FV2 protein
and against two control PfEMP1 domains. IgG was
purified from immune and preimmune sera from
the immunized animals. In addition, antibodies
raised against the DBL4ɛ domain from VAR2CSA,
which were previously found to be most effective in
preventing the binding of IEs to CSPG-b,14 were
purified and tested. These IgGs were tested for the
ability to inhibit the binding of FV2 to CSPG-h using
the surface plasmon resonance assay described
above. In each case, FV2 at a concentration of
10 nM was preincubated with different concentra-
tions of purified IgG before binding to a CSPG-h-
coated surface was assessed. While the control IgG
showed no effect on the ability of FV2 to bind to
CSPG-h, IgG from rats immunized with the recom-binant VAR2CSA protein inhibited this interaction,
with complete inhibition at a total IgG concentration
of 100 nM (Fig. 3). These IgGs were more effective
than the antibodies raised against the single DBL4ɛ
domain protein.
Inhibition of IE binding to CSPG using
VAR2CSA-specific antibodies
To examine the reactivity of IgG induced against
FV2 in rats, we used erythrocytes infected with the
homologous FCR3 parasite line. Expression of
VAR2CSA was continuously selected for by pan-
ning the IE on BeWo cells, as described previously.23
The resulting parasite line was recognized by
malaria endemic plasma in a sex-specific manner
and bound specifically to CSPG-b (data not shown).
The reactivity of FV2-specific IgG was benchmarked
against DBL4ɛ-specific serum and IgG. The DBL4ɛ
domain was recently shown to be the construct that
induces the strongest parasite-inhibitory response.14
In addition, we compared the reactivity to pools of
human serum. We found a 14-fold higher recogni-
tion of the IEs by IgG in the FV2-specific serum
compared to the DBL4ɛ-specific serum based on the
mean fluorescence intensity (MFI) (Fig. 4a). The
differences between the intensity of IgG staining
using FV2-specific serum and that using monodo-
main-specific labeling and human pool labeling are
exemplified in Fig. 4b. The functional capacity of the
induced IgG to inhibit the binding of IEs to CSPG-b
was measured in a static assay using a pipetting
robot (Biomek; Beckman Coulter) to remove un-
bound IEs from CSPG-b-coated wells.
Binding in the presence of IgG from FV2-
immunized rats was less than 10% of binding in
media alone. Strongly inhibitory antibodies were
already detectable after the second FV2 immuniza-
tion. IgG from rats immunized with DBL4ɛ of
Fig. 4. Reactivity against native VARCSA on the surface of FCR3 IEs. Groups of three rats were immunized with
DBL4ɛ or FV2 recombinant proteins. The reactivity of the induced IgGwasmeasured using flow cytometry and inhibition
of binding assays. (a) Measurements of IgG levels in serum after two and three immunizations against native VAR2CSA
expressed on IEs by flow cytometry. The reactivity shown is the ratio of negative controls (MFI test/MFI negative control).
The negative controls were stained only by secondary fluorescein-isothiocyanate-conjugated anti-rat IgG (no rat IgG). The
dotted line indicates the negative cutoff. (b) Examples of histograms of IEs (ethidium-bromide-positive cells) stained by
IgG in sera. Filled histograms from the left: not immunized (rat 1a); DBL4ɛ (rat 3b after the third immunization), and FV2
(rat 2c after the third immunization). Dotted histograms from the left: Danish naïve pool, male immune pool, and female
immune pool. (c) Inhibition of IE binding to decorin (CSPG-b) using serum in a 1:8 concentration. The dotted line indicates
the level of no inhibition. (d) Left: Titration of inhibitory reactivity in serum pools of three rats or pools of serum from 10
individual naïve Danes, 10 Tanzanian males, and 10 Tanzanian females. Right: Titration of purified IgG from pools of
three rats immunized with DBL4ɛ, FV2, or DBL6 (negative control). All error bars indicate standard errors of the means.
*This rat was sacrificed for monoclonal IgG production before the third immunization.
830 Expression of Functional Full-Length VAR2CSAVAR2CSA, the most potent inducer of inhibitory
antibodies to date, showed considerably lesser
activity than the anti-FV2 antibodies (Fig. 4c). This
was further substantiated by comparing inhibitory
activities in dilution series. Sera from FV2-immu-
nized rats at a dilution of 1:256 inhibited to the same
level as the serum from pregnant women at a
dilution of 1:5, and anti-FV2 antibodies showed the
same level of inhibition at 0.03 mg/ml as anti-DBL4ɛ
antibodies at 1 mg/ml (Fig. 4d). Antibodies against
FV2 were tested for the ability to inhibit a
VAR2CSA-expressing heterologue parasite isolate(7G8) binding to CSPG-b. This was performed in a
Petri dish assay using 1 mg/ml IgG, and bound IEs
were stained and counted. Preliminary data showed
that the FV2 antibodies inhibited 7G8 binding to
CSPG-b by around 70% (data not shown).Discussion
The majority of pathogens that attach to the host
endothelium seem to exploit the abundant and
highly sulphated GAG heparan sulphate as a
§http://www.geneart.com
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contrast, in malaria infection during pregnancy, the
adhesion of IEs to intervillous spaces of the placenta
is highly specific for CSA.25 Understanding the
mechanism underlying this unique CSA interaction
is central to the design of an optimal vaccine that can
abrogate IE adhesion in the placenta and protect
pregnant women against the adverse effects of PAM.
Until recently, it was believed that the domains of
PfEMP1 proteins are ordered as ‘beads on a string,’
with different individual domains able to bind
independently to receptor molecules. Based on
this, the obvious approach for identifying the
functional parts of PfEMP1 has been to analyze the
binding properties of the corresponding domains
expressed as single recombinant proteins.14,15,26–28
Consequently, this has been the main focus of PAM
vaccine development, with considerable effort
exerted to define a single domain of VAR2CSA
that can be included in a vaccine. In the light of
recently published data, it has become apparent that
single domains of VAR2CSA do not show the CSA-
specific binding associated with IEs isolated from
placental tissue.20,21 The DBL2X, DBL3X, and
DBL6ɛ domains that have been shown to bind
CSA in vitro also bind very well to heparan sulphate
and heparin, with DBL3X and DBL6ɛ binding with a
higher affinity to heparin than to CSA. These
findings have raised questions regarding the inter-
action between VAR2CSA and CSA, leading to the
suggestion that the CSA-specific binding site of
native VAR2CSA is due to higher-order arrange-
ments of the domains or that other CSA-specific
binding molecules are involved. Following this, the
production of the whole extracellular part of
VAR2CSA was a priority in attempts to unravel
the true binding mechanism.
Here, we present for the first time the production
of the entire extracellular part of VAR2CSA from the
FCR3 parasite (FV2), expressed as a soluble secreted
protein in a eukaryotic expression system. Sufficient
yields were obtained to allow us to both study the
GAG-binding properties of FV2 and test the ability
of this protein to induce functional antibodies in
rats. The FV2 protein bound to CSPG-h with an
affinity of 0.36 nM, a factor 100,000-fold stronger
than that observed for any single domain of
VAR2CSA. In addition, this interaction was CSA-
specific, with the low-sulphated CSA present in
CSPG-b inhibiting the VAR2CSA–CSPG interaction
to the greatest degree. The fact that FV2 can bind
specifically to human placental CSPG with high
affinity suggests that native VAR2CSA on the
surface of IEs does indeed contain the determinants
needed to specifically and directly interact with CSA
and does not require a bridging molecule. In
addition, these results imply that the CSA binding
site is complex in the sense that it is composed of
residues from several domains, which need to be
assembled in a correctly folded VAR2CSA protein to
form the CSA-specific binding site.
Rat antibodies induced by a recombinant DBL4ɛ
protein from VAR2CSA of FCR3 are able to inhibitIE binding to the CSA of the homologous parasite
FCR3 by 90%.14 Since the CSA-binding region of
VAR2CSA has not been defined, it is not clear how
the inhibitory DBL4ɛ antibodies act to abrogate the
interaction with CSA. These antibodies may work
by targeting a few critical residues in the DBL4ɛ
domain that is part of the CSA binding site, by
blocking access to a neighboring binding site, or by
preventing the formation of a higher-order structure
of VAR2CSA needed to form the CSA binding
pocket. In this case, introduction of a DBL4ɛ-based
vaccine might lead to a strong selection for CSA-
binding parasites with different amino acids in these
positions in DBL4ɛ. Accordingly, it would be
preferable to target highly conserved residues—or
as many residues as possible—that are involved in
receptor–ligand interaction to reduce the possibility
of creating a population of parasites that have
mutated in the receptor binding site without losing
the ability to bind to the receptor. The FV2 construct,
which contains the whole CSA binding site, will be
particularly useful in overcoming these challenges.
As presented in this study, the FV2 protein induces a
highly potent and robust humoral response in rats,
and FCR3 IE binding to CSA is completely blocked
by these antibodies, which also seem to be cross-
reactive with a heterologue isolate. These results are
promising for vaccine development and open the
way to future studies that will include analysis of
the breadth of the antibody response, the mecha-
nism of inhibition, and the development of protocols
for the optimization of protein production to
increase the yield of this large antigen.Materials and Methods
P. falciparum cultures
Parasite culture was grown as previously described.29
In brief, parasites were maintained in a culture using 5%
hematocrit of human blood group O+ blood in a parasite
medium consisting of RPMI 1640 supplemented with
25 mmol/L sodium bicarbonate (Sigma-Aldrich),
0.125 μg/ml gentamicin, 0.125 μg/ml Albumax II (Invi-
trogen), and 2% normal human serum. To select for
VAR2CSA expression, we repeatedly panned IEs on
BeWo cells, as described previously.23 All isolates were
negative for mycoplasma and were regularly genotyped
using nested GLURP and MSP-2 primers in a single PCR
step.
Codon optimization and cloning
The FCR3 var2csa gene was optimized for expression in
Trichoplusia ni cells using the software GeneOptimizer§
and subsequently synthesized by Geneart (Regensburg,
Germany). Briefly, subgenetic fragments were assembled
from synthetic oligonucleotides using a single-step PCR-
based method. The full-length synthetic and optimized
DNA was fused by ligation of the respective subgenetic
832 Expression of Functional Full-Length VAR2CSAfragments and cloned, and the insert was verified by
sequencing. The codon-optimized gene sequence is
deposited at GenBank with accession no. GU249598. The
var2csa gene was subcloned into the baculovirus vector
pAcGP67-A (BD Biosciences) modified to contain a V5
epitope upstream of a His tag at the C-terminal end of the
construct. Linearized Bakpak6 Baculovirus DNA (BD
Biosciences) was cotransfected with pAcGP67-A into Sf9
insect cells for the generation of recombinant virus
particles. The control PfEMP1 proteins used to induce
control IgG for the binding assay were based on 3D7
VAR4 CIDR (PFD1235w) and FCR3 DBL3γ, as defined by
Nielsen et al.14
Protein expression and purification
High-Five insect cells grown in 600 ml of serum-free
media (10486; GIBCO) were infected with 18 ml of the
second amplification of the recombinant virus particles.
After 2 days of induction, the cells were centrifuged
(8000g, 4 °C, 10 min), and the supernatant was filtered
using two 10-kDa NMWC PES membranes (0.45 μm) (56-
4112-04; GE Healthcare) with a total surface area of
200 cm2. The supernatant was then concentrated to 30 ml
and diafiltrated six times on an ÄKTA cross-flow (GE
Healthcare) with buffer A [10 mM sodium phosphate
(pH 7.4) and 500 mM NaCl]. Retentate was recovered
from the system and filtered (0.2 μm), yielding a final
volume of 40 ml. A total of 10 ml of the retentate was
loaded onto a 1-ml HisSelect column (H8286; Sigma-
Aldrich), a 1-ml Capto S HP column (17-5441-22; GE
Healthcare), and a 1-ml Heparin HP column (17-0406-01;
GE Healthcare). Before loading on the HisSelect column,
150 μl of 1 M imidazole (pH 7.4; Sigma-Aldrich) was
added to the sample, giving a final imidazole concentra-
tion of 15 μM. The samples for the Capto S HP and
Heparin HP columns were diluted 1:10 with 10 mM
sodium phosphate (pH 7.4), giving a final salt concentra-
tion of 50 mM NaCl. The bound protein was eluted with
buffer A+200 mM imidazole (HisSelect) or a salt gradient
ranging from 50 mM to 1000 mM NaCl (Capto S HP and
Heparin HP).
Rat immunizations and IgG preparations
Rat anti-sera were produced by injection of 30 μg of
recombinant protein in Freund's complete adjuvant,
followed by two booster injections of 15 μg of protein in
Freund's incomplete adjuvant at 3-week intervals. Anti-
sera were collected 8 days after the final boosting injection.
All procedures regarding animal immunizations complied
with European and national regulations. All immuniza-
tions induced antibodies against the recombinant pro-
teins, as measured by ELISA of the final bleed. IgG was
purified by manually passing 0.5 ml of rat immune serum
through a column packed with Recombinant Gamma-
Bind™G type 2 coupled to Sepharose™ 4B, in accordance
with the manufacturer's recommendations (GE Health-
care), and bound IgG was eluted with Tris–glycine
(pH 2.4) and dialyzed against phosphate-buffered saline.
Anti-DBL4ɛ IgG was the same IgG used by Nielsen et al.14
Flow cytometry
Flow cytometry was used to test the reactivity of rat
serum to VAR2CSA on the surface of the IEs. In brief,
parasite cultures were enriched to contain late-trophozo-ite-stage and schizont-stage parasites by exposure to a
strong magnetic field. Aliquots (2×105 IE) were labeled
with ethidium bromide and sequentially exposed to 10 μl
of rat serum and 1 μl of anti-rat IgG FITC (Zymax;
Invitrogen). Data were acquired using an FC500 flow
cytometer (Beckman Coulter). All samples relating to a
particular parasite isolate were processed and analyzed in
a single assay.
Parasite binding assays
Parasite binding assays with FCR3 IEs were performed
as previously described.29 Briefly, 2×105 tritium-labeled
late-stage IEs and 15 μl of rat serum or IgG in a total
volume of 100 μl were added in triplicate to wells coated
with 2 μg/ml of the commercially available CSPG, decorin
(CSPG-b; D8428; Sigma-Aldrich). The binding to CSPG-b
was abrogated by soluble CSA (C9819; Sigma-Aldrich)
and chondroitinase treatment (data not shown). After
incubation for 30 min at 37 °C, unbound IEs were washed
away by resuspension performed by a pipetting robot
(Beckman Coulter). The proportion of adhering IEs was
determined by liquid scintillation counting on Topcount
NXT (Perkin-Elmer).
Surface plasmon resonance measurements
Measurements were performed on a Biacore T100
instrument with a constant flow rate of 30 μl/min.
Biotinylated CSPG-h was obtained from MR4 (deposited
by C. Gowda) and coupled to an streptavidin chip
(Biacore). CSPG-h was dissolved to a concentration of
10 μg/ml in HBS buffer [10 mM Hepes (pH 7.4), 150 mM
NaCl, 50 μM ethylenediaminetetraacetic acid, and 0.05%
Tween 20] and flowed through channel 2 until the
response had increased by 400 RU. Flow cell 1 was left
as a control surface.
Proteins were equilibrated into HBS buffer using PD10
columns (Amersham Biosciences). Both channels were
equilibrated with HBS buffer before the injection of
purified VAR2CSA protein. The level of specific binding
was obtained from the subtraction of the response from
channel 2 from that from channel 1. After each injection,
both channels were regenerated with a 30-μl injection of
1 M NaCl. This procedure led to the recovery of the
original baseline and regenerated a CSPG-h surface that
could bind reproducibly to subsequent injections of FV2.
Data were analyzed using the BIAevaluation software
(version 1.1.1) to fit the kinetics of association and
dissociation.
For competition experiments, GAGs were obtained
from Sigma-Aldrich: CSA from bovine trachea (C9819),
CSC from shark cartilage (C4384), dermatan sulphate
from porcine intestinal mucosa (C3788), heparin from
porcine intestinal mucosa (H9399), hyaluronic acid from
human umbilical cord (53750), and HSPG from mouse
sarcoma (H4777). Human placental CSPG is difficult to
obtain in sufficient amounts for inhibition assays and
parasite binding assays; therefore, the commercially
available CSPG, decorin (CSPG-b), from bovine articular
cartilage (D8428) was used in some experiments. Each
GAG was dissolved in HBS buffer up to 1 mg/ml, and
these stocks were mixed with the FV2 protein to produce
samples with a final concentration of 1 nM FV2 and a
range of GAG concentrations (1–10 ng/ml) in HBS
buffer. These were incubated for a minimum of 30 min,
and Biacore measurements were taken as described
above.
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